These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 27127191)

  • 1. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes.
    Ikeda H; Shiku H
    Cancer Immunol Immunother; 2015 Jul; 64(7):903-9. PubMed ID: 26041411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive T cell therapy: points to consider.
    Yee C
    Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.
    Tay JC; Zha S; Wang S
    Immunotherapy; 2017 Dec; 9(16):1339-1349. PubMed ID: 29185393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.
    Badieyan ZS; Hoseini SS
    Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):283-288. PubMed ID: 29427174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
    Sukari A; Abdallah N; Nagasaka M
    Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principles of adoptive T cell therapy in cancer.
    Met Ö; Jensen KM; Chamberlain CA; Donia M; Svane IM
    Semin Immunopathol; 2019 Jan; 41(1):49-58. PubMed ID: 30187086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering T cells for adoptive therapy: outsmarting the tumor.
    Kunert A; Debets R
    Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma.
    Qureshi HA; Lee SM
    Curr Treat Options Oncol; 2019 Mar; 20(4):31. PubMed ID: 30874960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
    Arnaud M; Bobisse S; Chiffelle J; Harari A
    Front Immunol; 2021; 12():701636. PubMed ID: 34394096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
    Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
    Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer Immunotherapy: Theory and Application.
    Chen G; Bodogai M; Tamehiro N; Shen C; Dou J
    J Immunol Res; 2018; 2018():7502161. PubMed ID: 30035133
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors.
    Zander R; Cui W
    Hum Vaccin Immunother; 2017 Oct; 13(10):2269-2271. PubMed ID: 28708956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
    Rath JA; Arber C
    Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy using tumor antigen-reactive T cells.
    Choi BK; Kim SH; Kim YH; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):235-245. PubMed ID: 29370726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The recent advancement of TCR-T cell therapies for cancer treatment.
    Zhao X; Shao S; Hu L
    Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):663-674. PubMed ID: 38557898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Neoantigens.
    Schumacher TN; Scheper W; Kvistborg P
    Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.